Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer (“CMO”) of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius. Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time Globe Newswire 10/29 08:30 ET Caladrius Biosciences to … Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that the Company will report its third quarter financial results for the three and nine months ended September 30, 2020 on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. It is a privilege to work for this company. - Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020. Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction. Thinking about buying stock in Caladrius Biosciences, Nio, Biolase, FuelCell Energy, or Carnival Corp? Annual stock financials by MarketWatch. There's no doubt that money can be made by owning shares of unprofitable businesses. Caladrius Biosciences Announces $25.0 Million Private Placement, Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021, Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio UpdateProgram strategy and prioritization supports projection of available capital through 2021, Caladrius Biosciences to Webcast Live at Life Sciences Investor ForumCompany invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com, Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical OfficerThe Company retains Robert Honigberg, M.D., as interim Chief Medical Officer, Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November, Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors, Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time, Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°, Biopharma Update on the Novel Coronavirus: October 13, Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage, Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa, Caladrius Biosciences to Present at the BIO Investor Forum Digital, Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th, Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum, Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan, Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Thank you for your request. For more information, please visit: https://bit.ly/3qAcA9I Learn how to enable cookies. H.C. Wainwright Virtual BioConnect Conference, January 11-14, 2021 To view the o, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has completed its year-end strategic portfolio product review to optimize the development strategy and priority of each of its programs for 2021 and beyond. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has received trademark registration from the Japan Patent Office (“JPO”) for the Company’s use of HONEDRA® as the brand name for CLBS12, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22 nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. 3/13/2017. Presentation Details: Date & Time: Tuesday, Septembe, © 1985 - 2021 BioSpace.com. Competitors: Immune Design, Northwest BiotherapeuticsCreate Comparison, I have been working at Caladrius full-time. Changes wont be saved until you sign up for an Enhanced Profile subscription. Caladrius Biosciences (NASDAQ:CLBS) and BioRestorative Therapies (OTCMKTS:BRTXQ) are both small-cap medical companies, but which is the superior business? Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. View the CLBS U.S. Securities and Exchange Commission reporting information. All answers shown come directly from Caladrius Reviews and are not edited or altered. January 21, 2021 Caladrius Biosciences … About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse … A Sales Representative will be in contact with you with your custom quote. All rights reserved. 9 Attention-Grabbing Cover Letter Examples, 10 of the Best Companies for Working From Home, The Top 20 Jobs With the Highest Satisfaction, 12 Companies That Will Pay You to Travel the World, 7 Types of Companies You Should Never Work For, How to Become the Candidate Recruiters Can’t Resist, 11 Words and Phrases to Use in Salary Negotiations, 10 High-Paying Jobs With Tons of Open Positions, Negotiating Over Email? 07920 Very smart, team oriented people everywhere! Caladrius Biosciences Inc. quarterly stock financials by MarketWatch. All content is posted anonymously by employees working at Caladrius. Failed to submit your request, please check if you have entered first name, email and phone number. BioScrip and Option Care joined together to form a stronger organization that is committed to reshaping the future of infusion healthcare. News. We are developing first-in-class cell … See what people working for Caladrius Biosciences are saying. How to Answer: What Are Your Strengths and Weaknesses? Caladrius Biosciences. No summer Fridays, but who knows that could change. Basking Ridge New Jersey Search for job openings at Caladrius Biosciences. Download the investor presentation - earnings call slides. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech and … Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health. Overview Jobs About us Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. 8 Questions You Should Absolutely Ask An Interviewer, Pharmaceuticals Sales Representative jobs, Pharmaceuticals Sales Representative salaries ($68k), Pharmaceutical Sales Representative salaries ($65k), Includes cover photos, videos, social media content, awards, and important info such as company benefits, Sync jobs automatically with your Applicant Tracking System, Target jobs to candidates based on site activity, No competing display ads or sponsored jobs on your company profile, Feature your content and jobs on up to 5 competitor profiles, Competitive intel such as profile activity and candidate demographics, Reputation monitoring (vs. competitors and by job title and location), Advanced review and interview filters with additional insights including sentiment analysis. Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losers Jan. 20, 2021 10:56 AM ET Obalon Therapeutics, Inc. (OBLN) By: … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. This presentation will be available on demand for BIO I. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that management will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17, 2020.